The Use of Antibiotics in COVID-19 Therapy in RSUP Dr. Sardjito Yogyakarta

https://doi.org/10.22146/farmaseutik.v19i1.71638

Putri Dina Mahera Laily(1*), Tri Murti Andayani(2), Ika Puspitasari(3)

(1) Universitas Gadjah Mada
(2) 
(3) Fakultas Farmasi, Universitas Gadjah Mada
(*) Corresponding Author

Abstract


As a newly emerging disease initially identified at the end of 2019 in Wuhan, China, COVID-19 has various therapeutic options. The current COVID-19 treatment in Indonesia refers to the licensed treatment based on the Emergency Used Authorization from BPOM, which lists many approved antibiotic therapies. However, inappropriate use of antibiotics is known to have an adverse impact of resistance. Therefore, studies on the use of antibiotics in health care facilities, including hospitals, are pivotal, especially in the management of newly emerging disease of COVID-19. This study aims to describe the use of antibiotics as a therapeutic option for COVID-19 treatments in RSUP Dr. Sardjito Yogyakarta. The research used descriptive analytic method by involving patients, who were tested positive for COVID-19 in the period of February to September 2020 in Dr. RSUP Sardjito Yogyakarta, as the research subjects. Data were collected retrospectively using the drug use listed in the medical records. Data were analyzed based on patient characteristics, antibiotic profile, and final prognosis of treatment outcome. This study revealed that the highest cases occurred in men with 69.4%. The productive age group of 21 to 60 years old was known to be the age group with the highest COVID infection (64%). The most widely used antibiotics were azithromycin (56.5%) and levofloxacin (32.9%). The use of antibiotic therapy in COVID-19 patients at RSUP Dr. Sardjito Yogyakarta has proven to be quite effective with a prognostic rate of 76.5% for patients experiencing recovery.


Keywords


Use of Antibiotics, Therapy, COVID-19

Full Text:

PDF


References

BPOM (2020) Pedoman Pelayanan Publik di Bidang Obat Dalam Kondisi Pandemi COVID-19. Burhan, E. et al. (2020) PEDOMAN TATALAKSANA COVID-19 Edisi 3 TIM EDITOR Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI). Damle, B. et al. (2020) “Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19,” Clinical Pharmacology and Therapeutics. Nature Publishing Group, pp. 201–211. doi:10.1002/cpt.1857. Devaux, C.A. et al. (2020) “New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?,” International Journal of Antimicrobial Agents, 55(5). doi:10.1016/j.ijantimicag.2020.105938. Guan, W. et al. (2020) “Clinical Characteristics of Coronavirus Disease 2019 in China,” New England Journal of Medicine, 382(18), pp. 1708–1720. doi:10.1056/nejmoa2002032. Karampela, I. and Dalamaga, M. (2020) “Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?,” Archives of Medical Research, 51(7), pp. 741–742. doi:10.1016/j.arcmed.2020.06.004. Kemenkes RI (2020) Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19), Germas. Parasher, A. (2021) “COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment,” Postgraduate Medical Journal. BMJ Publishing Group, pp. 312–320. doi:10.1136/postgradmedj-2020-138577. Rachmawati, S., Fazeri, R.L. and Norcahyanti, I. (2020) “Gambaran Penggunaan Antibiotik di Bangsal Penyakit Dalam RSUD Bangil Kabupaten Pasuruan,” JPSCR: Journal of Pharmaceutical Science and Clinical Research, 5(1), p. 12. doi:10.20961/jpscr.v5i1.35254. Setiadi, A.P. et al. (2020) “Tata Laksana Terapi Pasien dengan COVID-19: Sebuah Kajian Naratif,” Indonesian Journal of Clinical Pharmacy, 9(1), p. 70. doi:10.15416/ijcp.2020.9.1.70. Seyed Hosseini, E. et al. (2020) “The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies,” Virology, 551, pp. 1–9. doi:10.1016/j.virol.2020.08.011. Tobaiqy, M. et al. (2020) “Therapeutic management of patients with COVID-19: a systematic review,” Infection Prevention in Practice, 2(3), p. 100061. doi:10.1016/j.infpip.2020.100061. Wang, J. et al. (2020) “Efficacy and safety of antibiotic agents in children with COVID-19: a rapid review,” Annals of Translational Medicine, 8(10), pp. 619–619. doi:10.21037/atm-20-3300.



DOI: https://doi.org/10.22146/farmaseutik.v19i1.71638

Article Metrics

Abstract views : 743 | views : 450

Refbacks

  • There are currently no refbacks.


Majalah Farmaseutik Indexed by:

   
 
Creative Commons Licence
 
 
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.